e-learning
resources
Paris 2018
Monday, 17.09.2018
Clinical aspects of hypersensitivity pneumonitis (HP) and CTD-ILD: diagnosis, monitoring and treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Usefulness of pulsed cyclophosphamide in Interstitial Lung Disease (ILD)
C. Kong (Portsmouth, United Kingdom), O. Adeagbo (Portsmouth, United Kingdom), R. Hooper (Portsmouth, United Kingdom), V. Titmuss (Portsmouth, United Kingdom), S. Babu (Portsmouth, United Kingdom)
Source:
International Congress 2018 – Clinical aspects of hypersensitivity pneumonitis (HP) and CTD-ILD: diagnosis, monitoring and treatment
Session:
Clinical aspects of hypersensitivity pneumonitis (HP) and CTD-ILD: diagnosis, monitoring and treatment
Session type:
Thematic Poster
Number:
2982
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Kong (Portsmouth, United Kingdom), O. Adeagbo (Portsmouth, United Kingdom), R. Hooper (Portsmouth, United Kingdom), V. Titmuss (Portsmouth, United Kingdom), S. Babu (Portsmouth, United Kingdom). Usefulness of pulsed cyclophosphamide in Interstitial Lung Disease (ILD). 2982
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Inmunosuppresor therapy effectivness in Interstitial Lung Disease (ILD) associated Connective Tisuue Disease(CTD).
Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Year: 2017
Usefulness of electronic nose in detection of Interstitial Lung Diseases (ILD)
Source: International Congress 2019 – Biomarkers and beyond in idiopathic interstitial pneumonia
Year: 2019
Interstitial Lung Disease (ILD) in aluminium welders
Source: Virtual Congress 2020 – Occupational and environmental causes of respiratory disease
Year: 2020
Unclassifiable Interstitial Lung Disease (ILD). Why?
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021
Assessment of Treatment Response in Granulomatous Lymphocytic Interstitial Lung Disease (GLILD)
Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment
Year: 2019
Benefit of steroid-free treatment compared to standard therapy (ST) in pulmonary sarcoidosis
Source: International Congress 2014 – ILDs 5
Year: 2014
Combined pulmonary fibrosis and emphysema: A report from the Hellenic Interstitial Lung Diseases group
Source: Annual Congress 2010 - Different patterns of interstitial lung disease
Year: 2010
Gender perspective in Interstitial Lung Diseases (ILD)
Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment
Year: 2019
Pulmonary function changes during treatment with rituximab in patients with rheumatoid arthritis
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
The incidence of Progressive Fibrotic Interstitial Lung Diseases (PFILD) treatable with oral-antifibrotic therapy in a UK Specialist Interstitial Lung Disease clinic.
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020
Value of community based Pulmonary Rehabilitation (PR) for patients with Interstitial Lung Disease (ILD): A retrospective review
Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases
Year: 2019
Treatment of IPF with inhaled IFN-gamma; planning for a clinical trial
Source: International Congress 2014 – ILDs 3
Year: 2014
LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study
Source: International Congress 2014 – IPF and surroundings
Year: 2014
Utility of Lung Ultrasound in Interstitial Lung Disease - A Paradigm Shift
Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause
Year: 2020
Tracking crackles of Interstitial Lung Disease during sleep.
Source: International Congress 2018 – Sarcoidosis, interstitial lung diseases and various clinical problems
Year: 2018
Clinical effect of pirfenidone on incidence of lung carcinoma in chronic interstitial pneumonia
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
Hypersentivity pneumonitis in an Interstitial Lung Disease Unit, 5 years’ experience
Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause
Year: 2020
A Comparison of Pulmonary Rehabilitation Outcomes in Interstitial Lung Disease and Chronic Obstructive Pulmonary Disease
Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases
Year: 2019
Transbronchial Lung Cryobiopsy (TBLC) for Interstitial Lung Disease (ILD) can be safely done in patients with multiple medical comorbidities
Source: Virtual Congress 2020 – Interventional pulmonology: unity in diversity
Year: 2020
Predictive Findings of Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept